Posted on : | events
During the SFN 2024 edition in Chicago, Dr. Quentin Marlier, head of biology at Dendrogenix, will present a poster publication called “Improvement of neurological outcomes following Stroke or traumatic brain injury in mice treated with a novel first-in-class compound” to expose preclinical data regarding its lead compound DX243 in stroke and TBI model.